The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria

Ryan D. Gentzler*, Sarah E. Yentz, Melissa L. Johnson, Alfred W. Rademaker, Jyoti D. Patel

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Over the last decade, new cytotoxic treatments and targeted therapies have altered treatment paradigms for patients with metastatic non-small cell lung cancer (NSCLC).We sought to analyze the impact of histology and biomarker selection criteria on outcomes of clinical trials in metastatic NSCLC reported over the last decade at the American Society of Clinical Oncology (ASCO) Annual Meeting. Data were collected from ASCO abstracts of Phase II-IV clinical trials for patients with metastatic NSCLC from 2004-2014. 770 of 2, 989 identified metastatic NSCLC category abstracts met selection criteria. Despite a decline in the number of abstracts from 107 to 46 abstracts annually over this period, the proportion of trials with positive progression free survival (PFS) and overall survival (OS) outcomes has increased significantly. Trials with histology selection (6%) or molecular biomarker (15%) criteria were more likely to result in an improvement in PFS than those without selection criteria (21% vs. 8%, p50.0001 and 31% vs. 10%, p<0.0001, respectively). These data demonstrate profound changes in the clinical trial landscape over the last 10 years with significantly increasing proportion of trials with positive outcomes. These changes are likely attributed to the use of histology and biomarker selection criteria in clinical trial design.

Original languageEnglish (US)
Pages (from-to)3853-3858
Number of pages6
JournalCancer
Volume120
Issue number24
DOIs
StatePublished - Dec 1 2014

Keywords

  • Biomarkers
  • Individualized medicine
  • Metastasis
  • Non-small cell lung carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria'. Together they form a unique fingerprint.

Cite this